Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03301636
Title A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107)
Acronym NLG2107
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NewLink Genetics Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST